What laboratory tests are recommended for patients taking Ozempic (semaglutide)?

From the Guidelines

Regular laboratory monitoring is recommended while on Ozempic (semaglutide) to assess glycemic control, monitor for potential side effects, and evaluate improvements in cardiovascular risk factors. Before starting treatment, baseline labs should include:

• Hemoglobin A1C
• Fasting blood glucose
• Kidney function tests (BUN, creatinine, eGFR)
• Liver function tests
• Lipid panel
• Thyroid function tests Once on Ozempic,
• Hemoglobin A1C should be checked every 3-6 months to assess glycemic control 1
• Fasting blood glucose can be monitored more frequently at home
• Kidney and liver function tests should be repeated every 6-12 months, or more often if there are pre-existing conditions
• Lipid panels should be checked annually to monitor cardiovascular risk factors
• Patients with risk factors for pancreatitis should have pancreatic enzyme levels (amylase, lipase) monitored periodically Additionally, patients should have regular blood pressure measurements and weight checks at each clinical visit. These tests help evaluate Ozempic's effectiveness in controlling blood sugar, monitor for potential side effects affecting organ function, and assess improvements in cardiovascular risk factors, as Ozempic not only lowers blood glucose but can also have positive effects on weight, blood pressure, and lipid profiles 1.

From the Research

Laboratory Tests While on Ozempic

There are no specific laboratory tests recommended for patients taking Ozempic (semaglutide) that are directly mentioned in the provided studies. However, the following points can be considered:

• The studies focus on the safety and efficacy of semaglutide, including its effects on glycemic control, weight loss, and potential adverse events 2, 3, 4.
• Monitoring of patients on semaglutide may include assessment of:
  • Glycemic control (e.g., HbA1c levels) 2, 4
  • Body weight 2, 4
  • Adverse events, such as gastrointestinal symptoms (e.g., nausea, diarrhea) 2, 5
  • Lipase levels, as increased levels have been reported in some patients 5
• It is essential to note that the provided studies do not specifically address the question of recommended laboratory tests for patients on Ozempic.
• Healthcare providers may consider monitoring patients on semaglutide based on individual patient needs and medical history, but this is not explicitly stated in the provided studies.
• The studies do discuss the potential risks and adverse events associated with semaglutide, including thyroid cancer, but the incidence of thyroid cancer in semaglutide-treated patients was found to be less than 1% 5.